hybridized to the U95A microarray. Microarrays were washed and stained with streptavidin-conjugated phycoerythrin (SAPE) by using the Affymetrix GeneChip Fluidic Station 400. Staining intensity was antibody amplified by using a biotinylated anti-streptavidin Ab at a concentration of 3 mg/ml followed by a second SAPE stain and was visualized at 570 nm. All microarrays were scanned using fluorometric scanners (Hewlett Packard Gene Array Scanner; CA, U.S.A.). Data were extracted and analyzed using Affymetrix Microarray Suite, MicroDB and Data Mining Tool software.
RNase Protection Assay (RPA) RNA was extracted with TRIZOL directly in the cell culture dish. A pGEM-4Z vector containing a fragment of the hPAI-1 cDNA (bp 76-1682) was linearized with HincII, which digests within the hPAI-1 cDNA insert. In vitro transcription of this linearized vector with Sp6 RNA polymerase generates a 495-bp antisense riboprobe. A pAMP-1 vector (Gibco) containing a fragment of the human GAPDH cDNA (bp 43-531) was linearized with Nco1. In vitro transcription of this linearized vector with T7 RNA polymerase generates a 290-bp antisense riboprobe. RPA was carried out as previously described. 9) Immunoblotting Immunoblotting was performed for AKT and ERK1/2 MAPK analysis. Cells were lysed in lysis buffer [50 mM Tris-HCl, 2.5 mM EGTA, 1 mM EDTA, 10 mM NaF, 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride (PMSF) and 2 mM Na 3 VO 4 ]. Cell lysates (20 mg) were run on 12% SDS-PAGE, transferred to nitrocellulose membranes (Hybond ECL, Amersham), and incubated with phospho-AKT or phospho-ERK1/2 Abs at 4°C overnight. The membranes were then incubated with rabbit HRP-conjugated Ab. Membranes were stripped, and reprobed for total AKT and ERK1/2 proteins.
In Vitro Kinase Assay Soluble lysates were used to phosphorylate myelin basic protein (MBP). 9) Lysates were incubated with 1 mg of anti-ERK2 Ab overnight at 4°C, followed by an additional 1 h incubation with protein A/G beads (Pierce, IL, U.S.A.). The immunocomplexes were washed, then incubated for 20 min at 30°C in 20 ml of kinase buffer and 10 mg of MBP as the substrate for ERK. Substrate phosphorylation was stopped by boiling in sample buffer, followed by 12% SDS-PAGE and autoradiography.
Measurement of PAI-1 Protein Expression CRT-J13 and U87-T37 cells were plated at 2ϫ10 5 /well in six-well plates, and incubated with serum-free medium, CXCL12, TNF-a without or with CXCL12, TGF-b1 without or with CXCL12, or all three for 24 h. PAI-1 proteins from the collected supernatants were quantitated using ELISA system (American Diagnostica Inc., CT, U.S.A.).
Statistical Analysis One-way analysis of variance (ANOVA) was used to determine the significance of differences between treatment groups. The LSD method among post-hoc tests was used for multi-group comparisons. Statistical significance was accepted for p values of Ͻ0.05.
RESULTS

PAI-1 mRNA Expression Is Enhanced by CXCL12
We have previously shown that CXCR4 expressing human glioma cells produce chemokines such as IL-8, MCP-1 and IP-10 upon CXCL12 stimulation. 9) In parallel, microarray gene expression analysis was done to test whether CXCR4 expressing glioma cells, upon CXCL12 stimulation, express genes that play important roles related to brain tumor growth. Comparing gene expression profiles in unstimulated and CXCL12 (50 ng/ml) stimulated CRT-J13 cells for 3 h revealed upregulation of 25 genes out of 2043 on a selected human cancer array (Table 1) . Interestingly, we found PAI-1 mRNA expression among these upregulated genes is induced (4.6-fold) by CXCL12 stimulation. To confirm this result, CRT-J13 cells were stimulated with CXCL12 (50 ng/ml) for 0-24 h, then PAI-1 mRNA was analyzed by RPA. As shown in Fig. 1A , low constitutive PAI-1 mRNA was detected (lane 1), and CXCL12 treatment caused a time-dependent increase in PAI-1 mRNA expression, with optimal expression detected at 8 h (2.8-fold, lane 4). Comparable results were observed in CXCR4 positive U87-T37 cells (data not shown). Dose-response curves were obtained after treatment with CXCL12 in the range of 0.1-500 ng/ml for 6 h (Fig. 1B) . PAI-1 mRNA expression increased with increasing CXCL12 concentrations, reaching maximum 2.8-3.1-fold induction using 50-500 ng/ml. Two protected PAI-1 mRNA bands were detected; the upper band likely corresponds to a fragment of the 3.0 kb PAI-1 mRNA species and the lower band to the 2.2 kb PAI-1 mRNA as reported previously by Yamamoto et al. 14) To establish the specificity of this effect, neutralizing Abs to CXCL12 and CXCR4 were used, which abolished CXCL12-induced PAI expression (50% and 58%; Fig. 1C ). Mouse IgG had no effect in this system (4%), indicating that the increase in PAI expression was induced by CXCL12 through CXCR4.
The 
Beta 2-microglobulin (4.8) X04409 G(s) alpha (alpha-S1) (Gs component of adenylyl cyclase) (4.6) J04164
Interferon-inducible protein (IP-10) (4.6) J03764
Plasminogen Activator Inhibitor-1 (PAI-1) (4.6) U37146 Silencing mediator of retinoid and thyroid hormone (SMRT) (4.5) M62831 Transcription factor ETR101 (4.5) X95735 Zyxin (4.5) AL031670 Ferritin, light polypeptide-like 1 (4.5) M14199 Laminin receptor, 67 kDa (67LR) (4. CXCL12 has been shown to activate various signaling pathways through CXCR4. In particular, activation by CXCL12 of the ERK MAPK-/PI3-kinase-/G protein-mediated pathways leads to cell proliferation and gene induction. 6, 9) To examine the signaling pathways involved in CXCL12-induced PAI expression, CRT-J13 cells were stimulated with CXCL12 for 0-60 min, cells were lysed, and subjected to 12% SDS-PAGE. As shown in Fig. 2A , phosphorylation of AKT and ERK1/2 was seen after 5 min of CXCL12 stimulation (lane 3), and was sustained for 60 min (lane 7). Next, we deter- CRT-J13 cells were incubated with medium or with CXCL12 (0.1-500 ng/ml) for 6 h. RNA was analyzed by RPA. (C) Mouse IgG (10 mg/ml), anti-CXCL12 Ab (10 mg/ml), and anti-CXCR4 Ab (10 mg/ml) were preincubated with CRT-J13 cells for 30 min, and then CXCL12 (50 ng/ml) was incubated for 6 h and harvested for RPA. Constitutive expression of PAI-1 mRNA was set at 1.0, and CXCL12 treatment was compared to control levels to arrive at the fold induction value. CXCL12-induced PAI-1 mRNA expression was set at 0% inhibition, and each experimental condition was calculated to determine the % inhibition value compared to CXCL12 alone. All results are a representative of three separate experiments. Since the ERK MAPK-/Ga i -mediated signaling pathways are involved in the CXCL12-induced PAI-1 expression, we further assessed whether activation of ERK MAPK is dominated by G-protein signaling in these response. CRT-J13 were stimulated with CXCL12 for 5 min, cells were lysed, and subjected to immunoprecipitation with anti-ERK2 Ab, and then an in vitro kinase assay was performed. MBP was used as the substrate for ERK2. Figure 2C illustrates that MBP phosphorylation by ERK2 was seen after CXCL12 stimulation for 5 min (lane 2).
Pretreatment of cells with PTX (lane 3) and U0126 (lane 5) but not CTX (lane 4) or LY294002 (lane 6), inhibited CXCL12-induced ERK2 activation, indicating that ERK MAPK activation involves Ga i proteins.
Effect of TNF-a a and TGF-b b1 on PAI-1 mRNA and Protein Expression TNF-a and TGF-b stimulation in astrocytes have been reported to increase PAI-1 mRNA expression. 12, 13) We tested whether TNF-a or TGF-b, in conjunction with CXCL12, affected PAI-1 mRNA expression. CRT-J13 cells were treated with CXCL12 (50 ng/ml), TNF-a (2 ng/ml) without or with CXCL12, TGF-b1 (2 ng/ml) without or with CXCL12, or with all three for 6 h. As shown in . These results demonstrate that CXCL12, TNF-a and TGF-b1 can function in an additive manner to increase PAI-1 mRNA expression.
Accumulation of a specific mRNA in cells is not always accompanied by comparable induction of protein expression. Therefore, CXCR4 expressing CRT-J13 cells were treated with CXCL12 (50 ng/ml), TNF-a (2 ng/ml) without or with CXCL12, TGF-b1 (2 ng/ml) without or with CXCL12, or all three for 24 h, then supernatants were collected and analyzed for PAI-1 protein production by ELISA. PAI-1 protein expression increased by 1.8-fold upon CXCL12 stimulation, 2.1-fold induction by TNF-a, and by 3.9-fold by TGF-b1. Costimulation led to a 2.8-fold induction by CXCL12 plus TNFa, a 4.8-fold induction by CXCL12 plus TGF-b1, and a 7.2fold induction by all three when compared with unstimulated cells (Fig. 3B) . Similar results were observed using U87-T37 cells (data not shown). These results demonstrate that CXCL12, TNF-a and TGF-b1 have a similar additive effect on PAI-1 protein expression as that observed at the mRNA level.
DISCUSSION
In this study, we have obtained evidence that CXCL12 stimulation of CXCR4 positive astroglioma cells leads to the induction of PAI-1 mRNA and protein expression; U0126, an inhibitor of the ERK1/2 MAPK signaling, blocks CXCL12induced PAI-1 expression, and PTX, an inhibitor of Ga i proteins abrogates CXCL12 induction of PAI-1 expression. 576 Vol. 32, No. 4 However, we observed that the PI3-kinase-mediated signaling pathway is not involved in this response, although this pathway is known to be involved in cell proliferation in glioma cells. 6) The literature amply demonstrates that PAIs are involved in tumor growth, invasion and angiogenesis. 4) The data for PAI-1 involvement in angiogenesis is contradictory, with the observations that PAI-1 can either enhance or inhibit tumor growth and angiogenesis. 4, 15) However, a recent study suggests that the dual effects of PAI-1 in angiogenesis are dosedependent, 16) which may explain the observed functional differences. We observed that CXCL12 has additive effects with either TNF-a or TGF-b1 in increasing PAI-1 expression in glioma cells. Glioma cells produces TNF-a and TGF-b, 2) thus these cytokines are present in the microenvironment of GBMs and, in conjunction with CXCL12, may potentiate PAI-1 expression. To promote their growth, malignant gliomas stimulate the formation of new blood vessels through processes driven primarily by VEGF. 17) It has been recently reported that PAI-1 stimulates expression of vascular endothelial growth factor (VEGF) in the glioma cells, 18) and thereby induces endothelial cell migration and proliferation through upregulation of CXCR4. 19) Thus, PAI-1 released from glioma cells may contribute to angiogenesis of tumors.
CXCL12 and CXCR4 are detected at extremely low levels in normal brain, however, both are overexpressed in astroglioma tumor tissue, and the expression levels are correlated with tumor grade. 11) It has been demonstrated that introduction of CXCR4 monoclonal Abs in glioblastoma cells causes inhibition of cell proliferation. 6) We have previously demonstrated that CXCL12 increases IL-8 production in astroglioma cells and IL-8 has potent angiogenic properties, and elevated levels of IL-8 may be associated with GBMs. 20) Therefore, these observations demonstrate that the CXCL12/CXCR4 complexes, and angiogenic factors such as IL-8 and PAI-1, are aberrantly expressed in GBM tumor tissue, and may contribute in part to tumor growth and angiogenesis.
We employed cDNA microarray analysis to compare gene expression patterns in CXCL12 stimulated astroglioma cells. A listing of the 25 most highly expressed genes is shown in Table 1 . This list contains several genes such as thymosin beta-4 and c-myc binding protein-1 that have been reported to be associated with angiogenesis. 21, 22) Overexpression of the 67 kDa laminin receptor (67LR) is an independent prognostic factor in primary breast cancer, and correlates with the dissemination of tumor cells. 23) Thus, a number of the genes that are up-regulated by CXCL12 stimulation have been implicated in the angiogenic process, including IL-8, PAI-1, 67LR, collagen type-1 a1, and PDGF-b, 17, 24) suggesting that CXCL12 stimulation in glioma cells may contribute to these processes.
In summary, we demonstrate that PAI-1 mRNA and protein expression are increased upon CXCL12 stimulation in CXCR4 positive astroglioma cells. In addition, we demonstrate that the CXCL12 insult with TNF-a and TGF-b1 has an additive effect to in increase PAI-1 expression. Taken together, our results point to links between chemokines, in-flammatory cytokines, and the PAI-1 system in the glioma cells.
